Cord Blood America Says U.S., Worldwide Research Shows Umbilical Cord Blood Stem Cells Could Be Crucial in Combating Difficult to Cure Diseases

LAS VEGAS, Aug. 3 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (http://www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today said that clinical trials ongoing in the U.S. using umbilical cord blood in the treatment of cerebral palsy, high-risk hematologic cancer, injured spinal cords and Type 1 diabetes provide significant further evidence of the importance of storing umbilical cord blood at the time of birth.

"We are asked with some frequency why store these stem cells available only at birth.  On our web site at www.corcell.com is a list of more than 70 diseases that are already treated by these stem cells, including acute and chronic leukemia's, severe aplastic anemia, Hodgkin's Disease, a number of inherited metabolic diseases and immune system disorders and malignancies including Ewing Sarcoma and Sickle Cell Disease," said Matthew Schissler, co-founder and CEO.  "Once in a while, it is my duty and obligation to step away from the day-to-day and reflect on the larger scope of work in the umbilical cord blood stem cell arena.  In doing so, I recognize that our loyal shareholders may not be privy to all of the data we receive, involving the outstanding studies with these cells.  It is my hope that a simple statement such as this, can direct our shareholders to the resources publicly available."  

"What is truly exciting is that the National Institutes of Health at www.clinicaltrials.gov now lists clinical trials ongoing at such prestigious research institutions as Duke University and Memorial Sloan-Kettering Cancer Center to understand the possible usage of stem cell infusions for the treatment of intractable diseases, including Type I diabetes in children, cerebral palsy in children, chronic spinal cord injuries, lymphoma and other blood borne cancers," Mr. Schissler said.

"Also, there is research ongoing elsewhere in the world to use umbilical cord blood stem cells to combat Alzheimer's, cardiac disease, lupus, multiple sclerosis, muscular dystrophy, Parkinson's Disease, rheumatoid arthritis and stroke.  This truly is an excellent time to be involved in this sector as we work toward our goal of becoming the most significant stem cell company in the world," said Mr. Schissler.

About Cord Blood America

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry.  Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.  To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/.  For investor information, visit http://www.cordblood-america.com/.

SOURCE Cord Blood America, Inc.